- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05024097
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. (PANTHER)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Pragya Yadav, Ph.D.
- Phone Number: 646-962-2196
- Email: pry2003@med.cornell.edu
Study Contact Backup
- Name: Sharanya Chandrasekhar, M.S.
- Phone Number: 646- 962-3110
- Email: shc2043@med.cornell.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medical College
-
Principal Investigator:
- Pashtoon Kasi, M.D.
-
Contact:
- Encouse Golden, M.D.,Ph.D.
- Phone Number: 212-746-3650
- Email: eng2003@med.cornell.edu
-
Principal Investigator:
- Encouse Golden, M.D., Ph.D.
-
Contact:
- Sharanya Chandrasekhar, M.S.
- Phone Number: 646-962-3110
- Email: shc2043@med.cornell.edu
-
New York, New York, United States, 11355
- Recruiting
- New York Presbyterian Hospital - Queens
-
Contact:
- Pragya Yadav, Ph.D
- Phone Number: 6469622196
- Email: pry2003@med.cornell.edu
-
Contact:
- Hina Ali, M.D.
- Phone Number: 718-670-1541
- Email: hia4002@med.cornell.edu
-
Principal Investigator:
- Andrew Brandmaier, M.D.
-
New York, New York, United States, 11215
- Not yet recruiting
- Brooklyn Methodist Hospital - NewYork Presbyterian
-
Contact:
- Pragya Yadav, Ph.D.
- Phone Number: 6469622196
- Email: pry2003@med.cornell.edu
-
Contact:
- Mary Palmer, M.S.
- Email: map9505@med.cornell.edu
-
Principal Investigator:
- Hani Ashamalla, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.
Inclusion Criteria:
- Histologically confirmed diagnosis of adenocarcinoma of the rectum
- Age ≥ 18 years
- ECOG performance status 0-1
- cT3N0 or cT1-3N1
- 5cm from the anal verge
- Rectal cancer amenable to total mesorectal excision
- No evidence of distant metastases
- No prior pelvic radiation therapy
- No prior chemotherapy or surgery for rectal cancer
- No infections requiring systemic antibiotic treatment
- Hgb >8.0 gm/dL, PLT > 150,000/mm3, total bilirubin ≤ 1.5x upper limit of normal, AST ≤ upper limit of normal, ALT ≤ 3x upper limit of normal
- Female participants or reproductive potential, defined as not surgically sterilized and between menarche and 1 year post menopause, must have a negative serum pregnancy test within 4 weeks prior to initiation of study treatment
- Female participants of reproductive potential and male participants with female partners of reproductive potential must remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive measures from the start of study treatment until 30 days after the last dose of etrumadenant, 90 days after the last dose of zimberelimab, whichever is longer
- Women with childbearing potential who are negative for pregnancy (urine or blood) and who agree to use effective contraceptive methods. A woman of childbearing potential is defined by one who is biologically capable of becoming pregnant. Reliable contraception should be used from trial screening and must be continued throughout the study.
- Male subjects must also agree to use effective contraception.
Exclusion Criteria:
- Recurrent rectal cancer
- Primary unresectable rectal cancer is defined as a primary rectal tumor which, on the basis of either physical exam or pelvic MRI, is demed to be adherent or fixed to adjacent pelvic structures (en bloc resection wll not be achieved with negative margins).
- ≥4 regional lymph nodes each ≥10 mm on pelvic MRI
- Suspected T4 tumor
- Involved radial margin
- Serum creatinine level >1.5x the upper limit of normal
- Patients who have received prior pelvic radiotherapy
- QTc ≥480 msec using Fredericia's QT correction formula
Due to the potential risk for drug-drug interactions with etrumadenant, participants must not have had:
- Treatment with known BCRP substrates with a narrow therapeutic window, administered orally (e.g., prazosin, rosuvastatin) within 4 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of and throughout study treatment
- Treatment with known P-gp substrates with a narrow therapeutic window, administered orally (e.g., digoxin) within 4 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of study treatment
- Treatment with known strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort) and strong CYP3A4 inhibitors (e.g., clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, telithromycin, and voriconazole) within 4 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of study treatment
- Any gastrointestinal condition that would preclude the use of oral medications (e.g., difficulty swallowing, nausea, vomiting, or malabsorption)
- Prior treatment with an agent targeting the adenosine pathway
- History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins
- Patients with a history of any arterial thrombitic event within the past 6 months, - Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment would make them inappropriate candidates for entry into this study
- Patients with a history of prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
- Patients with a history of thrombotic episodes, such as deep venous thrombosis, pulmonary embolus, MI or CVA occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
- Patients receiving other anticancer or experimental therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibodiy therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibody, or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.
- Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to four weeks after the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiation therapy and etrumadenant (AB928)
Enrolled patients will receive Radiation therapy of 25 Gy in 5 fractions along with etrumadenant 150mg oral drug taken once daily.
this will then be followed by 9 cycles of FOLFOX in combination of etrumadenant and zimberelimab investigational drugs.
|
Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.
Patients will receive a radiation therapy dose of 25Gy in 5fx
After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab.
All patients will be offered adjuvant zimberelimab for up to one year.
After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab.
All patients will be offered adjuvant zimberelimab for up to one year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of treated patients who achieve complete pathologic response
Time Frame: Week 24
|
The primary endpoint is the proportion of treated rectal cancer patients who achieve a complete pathologic response. All patients will be offered surgical resection however those who achieve a clinical CR at the time of clinical response assessment may choose a non-operative management approach. Due to practicality the latter will be included as complete responders at the time of analysis for this trial. |
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients who experience treatment-related adverse events
Time Frame: Day 5 of radiation therapy
|
Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0
|
Day 5 of radiation therapy
|
Number of patients who experience treatment-related adverse events
Time Frame: 3 months
|
Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0
|
3 months
|
Number of patients who experience treatment-related adverse events
Time Frame: 6 months
|
Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0
|
6 months
|
Number of patients who experience treatment-related adverse events
Time Frame: 12 months
|
Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0
|
12 months
|
Number of patients who experience treatment-related adverse events
Time Frame: 60 months
|
Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0
|
60 months
|
Progression free survival
Time Frame: 36 months
|
PFS is defined as the duration of time from start of treatment to time of progression.
|
36 months
|
Overall survival
Time Frame: 60 months
|
Overall Survival is defined as the duration of time from start of treatment until death.
|
60 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Encouse Golden, M.D., Ph.D., Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-02023289
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
National Cancer Institute (NCI)TerminatedMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
Clinical Trials on Etrumadenant (AB928)
-
Arcus Biosciences, Inc.Gilead SciencesCompletedHealthy ParticipantsUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted
-
Arcus Biosciences, Inc.CompletedMelanoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Castration-resistant Prostate Cancer | Merkel Cell Carcinoma | GastroEsophageal CancerUnited States, Australia
-
Arcus Biosciences, Inc.CompletedColorectal Cancer | GastroEsophageal CancerUnited States, Australia
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingLung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung CancerUnited States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
-
Surface OncologyArcus Biosciences, Inc.CompletedProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Jennifer ChoeArcus Biosciences, Inc.WithdrawnHead and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Oropharynx Cancer | Oral Cavity Cancer | Oropharynx Squamous Cell Carcinoma | Pharynx Cancer | Larynx Cancer | Hypopharynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell CarcinomaUnited States
-
Catherine SpinaArcus Biosciences, Inc.RecruitingOligometastatic Prostate CancerUnited States
-
Washington University School of MedicineArcus Biosciences, Inc.Active, not recruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell CarcinomaUnited States
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingNon Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene MutationUnited States, Korea, Republic of, Singapore, Taiwan